Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK46256 in Advanced Solid Tumors
NCT07695142Phase 1Recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HSK46256 in solid tumor, sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Dose-Limiting Toxicities at 24 days and Maximum Tolerated Dose at 24 days. Started Aug 2026; status: recruiting.
02
Drugs
HSK46256
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07695142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07695142.